Tocotrienol isomers gamma-tocotrienol and alpha-tocotrienol may benefit those with high cholesterol-but delta-tocotrienol doesn’t, according to a new study.
Tocotrienol isomers gamma-tocotrienol and alpha-tocotrienol may benefit those with high cholesterol-but delta-tocotrienol doesn’t, says ingredients supplier Carotech (Edison, NJ), according to a new study.
The rabbit study was published in Molecular and Cellular Biochemistry and performed by researchers from the University of Connecticut School of Medicine. Rabbits were fed a cholesterol diet for 60 days. On the last 30 days, they were given either alpha-, gamma-, or delta-tocotrienols.
At the end of the study, blood cholesterol levels were significantly lower in the gamma- and alpha-tocotrienol groups (50% and 39%, respectively), while the company says that the delta-tocotrienol group showed no significant reductions.
Moreover, gamma- and alpha-tocotrienols were shown to improve cardiac function and to reduce myocardial infarct size in hypercholesterolemic hearts, while the delta form did not, the company says. (Gamma-tocotrienol showed the strongest effects here.)
“Each isomer in the tocotrienol family plays different roles in our health,” stated WH Leong, Carotech’s vice president, in a press release. “In terms of cardioprotection, this study once again proves that gamma- and alpha-tocotrienol play an important part in lowering blood cholesterol and protecting the heart from injuries following a heart attack. Contrary to the misinformation that one can find on the Internet, delta-tocotrienol is the least effective. This study is consistent with the researchers’ earlier findings published in [American Journal of Physiology in 2008].”
The company says the findings support its own ingredients, Tocomin and Tocomin SupraBio, which are described as full-spectrum tocotrienol complexes containing the highest levels of gamma and alpha-tocotrienols.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.